Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Authors
Vale, CBurdett, S
Rydzewska, L
Albiges, L
Clarke, Noel W
Fisher, D
Fizazi, K
Gravis, G
James, N
Mason, M
Parmar, M
Sweeney, C
Sydes, M
Tombal, B
Tierney, J
Affiliation
MRC Clinical Trials Unit at UCL, London, UKIssue Date
2015-12-21
Metadata
Show full item recordAbstract
Results from large randomised controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged. In order to investigate the effects of these therapies and to respond to emerging evidence, we aimed to systematically review all relevant trials using a framework for adaptive meta-analysis.Citation
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. 2015: Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(15)00489-1PubMed ID
26718929Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(15)00489-1